# Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

> **NCT02775916** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** CDZ173
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02775916
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2017-05-17
- **Final completion:** 2017-05-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02775916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02775916, "Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02775916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*